Guidelines on the use of high-dose intravenous immunoglobulin in dermatology

Alexander Enk, Anthony Ormerod, European Dermatology Forum Guideline Subcommittee

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The treatment recommendations presented for the use of IVIg in dermatology highlight the high status of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The high value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. A clear case therefore exists for making a treatment recommendation such as described above for the conditions mentioned. Because the mechanism of action of IVIG in vivo is still unclear, however, further efforts should be made to reach standard therapies for the affected patient groups. This would enable even larger case series conducted by different therapists at different sites to be evaluated. Orientation towards the guideline recommendations laid down here should create a basis for this. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.
Original languageEnglish
Pages (from-to)90-98
Number of pages9
JournalEuropean Journal of Dermatology
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Intravenous Immunoglobulins
Dermatology
Guidelines
Therapeutics
Stevens-Johnson Syndrome
General Practice
Autoimmune Diseases

Keywords

  • dermatology
  • humans
  • immunoglobulins, intravenous
  • skin neoplasms
  • IVIg
  • guidelines

Cite this

Enk, A., Ormerod, A., & European Dermatology Forum Guideline Subcommittee (2009). Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. European Journal of Dermatology, 19(1), 90-98. https://doi.org/10.1684/ejd.2008.0580

Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. / Enk, Alexander; Ormerod, Anthony; European Dermatology Forum Guideline Subcommittee.

In: European Journal of Dermatology, Vol. 19, No. 1, 01.2009, p. 90-98.

Research output: Contribution to journalArticle

Enk, A, Ormerod, A & European Dermatology Forum Guideline Subcommittee 2009, 'Guidelines on the use of high-dose intravenous immunoglobulin in dermatology', European Journal of Dermatology, vol. 19, no. 1, pp. 90-98. https://doi.org/10.1684/ejd.2008.0580
Enk, Alexander ; Ormerod, Anthony ; European Dermatology Forum Guideline Subcommittee. / Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. In: European Journal of Dermatology. 2009 ; Vol. 19, No. 1. pp. 90-98.
@article{63ea0aebb47c4f14aace9303702100b8,
title = "Guidelines on the use of high-dose intravenous immunoglobulin in dermatology",
abstract = "The treatment recommendations presented for the use of IVIg in dermatology highlight the high status of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The high value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. A clear case therefore exists for making a treatment recommendation such as described above for the conditions mentioned. Because the mechanism of action of IVIG in vivo is still unclear, however, further efforts should be made to reach standard therapies for the affected patient groups. This would enable even larger case series conducted by different therapists at different sites to be evaluated. Orientation towards the guideline recommendations laid down here should create a basis for this. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.",
keywords = "dermatology, humans, immunoglobulins, intravenous, skin neoplasms, IVIg, guidelines",
author = "Alexander Enk and Anthony Ormerod and {European Dermatology Forum Guideline Subcommittee}",
year = "2009",
month = "1",
doi = "10.1684/ejd.2008.0580",
language = "English",
volume = "19",
pages = "90--98",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "John Libbey Eurotext",
number = "1",

}

TY - JOUR

T1 - Guidelines on the use of high-dose intravenous immunoglobulin in dermatology

AU - Enk, Alexander

AU - Ormerod, Anthony

AU - European Dermatology Forum Guideline Subcommittee

PY - 2009/1

Y1 - 2009/1

N2 - The treatment recommendations presented for the use of IVIg in dermatology highlight the high status of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The high value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. A clear case therefore exists for making a treatment recommendation such as described above for the conditions mentioned. Because the mechanism of action of IVIG in vivo is still unclear, however, further efforts should be made to reach standard therapies for the affected patient groups. This would enable even larger case series conducted by different therapists at different sites to be evaluated. Orientation towards the guideline recommendations laid down here should create a basis for this. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.

AB - The treatment recommendations presented for the use of IVIg in dermatology highlight the high status of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The high value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. A clear case therefore exists for making a treatment recommendation such as described above for the conditions mentioned. Because the mechanism of action of IVIG in vivo is still unclear, however, further efforts should be made to reach standard therapies for the affected patient groups. This would enable even larger case series conducted by different therapists at different sites to be evaluated. Orientation towards the guideline recommendations laid down here should create a basis for this. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.

KW - dermatology

KW - humans

KW - immunoglobulins, intravenous

KW - skin neoplasms

KW - IVIg

KW - guidelines

U2 - 10.1684/ejd.2008.0580

DO - 10.1684/ejd.2008.0580

M3 - Article

C2 - 19171549

VL - 19

SP - 90

EP - 98

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 1

ER -